1061 — Essex Bio-Technology Share Price
0.000.00%
Last trade - 00:00- HK$2.49bn
- HK$2.12bn
- HK$1.67bn
- 89
- 72
- 96
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | 2.64 | ||
| Price to Free Cashflow | 9.97 | ||
| Price to Sales | 1.49 | ||
| EV to EBITDA | 4.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.91% | ||
| Return on Equity | 15.18% | ||
| Operating Margin | 23.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 978.11 | 1,637.66 | 1,317.71 | 1,736.97 | 1,669.82 | n/a | n/a | 5.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -25.11 | +51.84 | -24.47 | +8.97 | +5.86 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.
Directors
- Mia Je Ngiam CHM
- Haizhou Fang MDR (49)
- Lai Man Yau EDR (57)
- Hian Leng Malcolm Ngiam EDR (36)
- Xinzhi Wang OTH (51)
- Chi Ying Fung NID (60)
- Benoit Mauffrey NID (62)
- Mee Mooi Yeow NID (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 31st, 2000
- Public Since
- June 27th, 2001
- No. of Employees
- 1,450
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 567,006,000
- Address
- Room 2818,Chn Mrchnts Twr,Shn Tk Ctr
- Web
- http://www.essexbio.com/
- Phone
- +852 null25877838
- Auditors
- BDO LTD
Upcoming Events for 1061
Dividend For 1061.HK - 0.0600 HKD
Essex Bio-Technology Ltd Annual Shareholders Meeting
Similar to 1061
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Essex Bio-Technology share price?
As of Today at 20:31 UTC, shares in Essex Bio-Technology are trading at HK$4.38. This share price information is delayed by 15 minutes.
How has the Essex Bio-Technology share price performed this year?
Shares in Essex Bio-Technology last closed at HK$4.38 and the price had moved by +100% over the past 365 days. In terms of relative price strength the Essex Bio-Technology share price has outperformed the FTSE Developed Asia Pacific Index by +102.28% over the past year.
What are the analyst and broker recommendations for Essex Bio-Technology?
The overall consensus recommendation for Essex Bio-Technology is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Essex Bio-Technology dividend yield?
The Essex Bio-Technology dividend yield is 2.74% based on the trailing twelve month period.
Does Essex Bio-Technology pay a dividend?
Last year, Essex Bio-Technology paid a total dividend of HK$0.12, and it currently has a trailing dividend yield of 2.74%.Looking ahead, shares in Essex Bio-Technology are due to go ex-dividend on 2025-05-23 and the next dividend pay date is 2025-06-09.
When does Essex Bio-Technology next pay dividends?
Essex Bio-Technology are due to go ex-dividend on 2025-05-23 and the next dividend pay date is 2025-06-09. The historic dividend yield on Essex Bio-Technology shares is currently 2.74%.
How do I buy Essex Bio-Technology shares?
To buy shares in Essex Bio-Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Essex Bio-Technology?
As of the previous close price of HK$4.38, shares in Essex Bio-Technology had a market capitalisation of HK$2.49bn.
Where are Essex Bio-Technology shares listed?
Here are the trading details for Essex Bio-Technology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1061
What kind of share is Essex Bio-Technology?
Based on an overall assessment of its quality, value and momentum Essex Bio-Technology is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Essex Bio-Technology share price forecast for 2025?
The analyst consensus target price for shares in Essex Bio-Technology is HK$10.15. That is 131.82% above the last closing price of HK$4.38.
Analysts covering Essex Bio-Technology currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Essex Bio-Technology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Essex Bio-Technology. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +66.35%.
As of the last closing price of HK$4.38, shares in Essex Bio-Technology were trading +56.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Essex Bio-Technology PE Ratio?
The Essex Bio-Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$4.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Essex Bio-Technology?
Essex Bio-Technology's management team is headed by:
- Mia Je Ngiam - CHM
- Haizhou Fang - MDR
- Lai Man Yau - EDR
- Hian Leng Malcolm Ngiam - EDR
- Xinzhi Wang - OTH
- Chi Ying Fung - NID
- Benoit Mauffrey - NID
- Mee Mooi Yeow - NID